This clinical trial is focused on studying the effects of a medication called Povorcitinib in individuals with a skin condition known as vitiligo. Vitiligo is a condition where patches of skin lose their color, leading to lighter areas on the body. The study will specifically look at a type of vitiligo called nonsegmental vitiligo, which is the most common form and can appear on both sides of the body. Participants in the study will receive either Povorcitinib or a placebo, which is a substance with no active medication, to compare the effectiveness of the treatment.

The purpose of the study is to evaluate how well Povorcitinib works in improving the skin condition over a period of 52 weeks. Participants will take the medication in the form of a tablet by mouth. Throughout the study, researchers will monitor changes in the skin, particularly looking for improvements in the color of the skin on the face and body. The study aims to see if participants experience at least a 75% improvement in their skin condition by the end of the study period.

Participants will be involved in the study for about a year, during which they will have regular check-ups to assess their progress. The study will help determine if Povorcitinib is a safe and effective treatment option for people with nonsegmental vitiligo. This research could potentially lead to new treatment options for those affected by this skin condition.